
Gero.ai is a physics-enabled biotechnology company focused on developing therapeutics against chronic diseases and slowing down human aging. They utilize Large Health Models (LHMs) trained on longitudinal real-world human data, which are physics-based and interpretable, to predict health outcomes and discover novel treatments. The company collaborates with leading institutions like Harvard Medical School and has a scientific approach grounded in complex dynamic systems and deep neural networks. Gero.ai aims to hack aging by understanding, measuring, and controlling its progression, with a mission to cure root causes of chronic diseases. They have also established a collaboration with Pfizer to discover potential targets for fibrotic diseases.

Gero.ai is a physics-enabled biotechnology company focused on developing therapeutics against chronic diseases and slowing down human aging. They utilize Large Health Models (LHMs) trained on longitudinal real-world human data, which are physics-based and interpretable, to predict health outcomes and discover novel treatments. The company collaborates with leading institutions like Harvard Medical School and has a scientific approach grounded in complex dynamic systems and deep neural networks. Gero.ai aims to hack aging by understanding, measuring, and controlling its progression, with a mission to cure root causes of chronic diseases. They have also established a collaboration with Pfizer to discover potential targets for fibrotic diseases.
About Us:
In
GERO.AI , our mission is to decelerate human aging and develop innovative therapies for chronic conditions. We utilize physics-based foundational models trained on longitudinal data (e.g. UK Biobank). By extracting continuous biological latents (metabolic, immune, and biological age), we model health resilience and functional units far beyond the limitations of ICD-10 codes. Our genetics-driven causal AI pipeline integrates human genetics with multi-omics data to identify novel treatments and accelerate drug discovery.
Position Overview:
We're seeking a Statistical Geneticist, Computational Biologist, or Bioinformatics Scientist with expertise in deep learning applications for variant annotation and functional genomics. You'll advance our target discovery platform by working with AI models, multi-omics data, and large-scale population genetics datasets to identify therapeutic targets and speed up drug discovery. Key tasks include processing genetics (GWAS/PheWAS), building reliable pipelines; implementing state-of-the-art methods; and developing production-ready code. The ideal candidate has strong computational genomics skills and a passion for translating biological data into drug development insights.
Key Responsibilities:
Data management & preprocessing:
Handle tabular data, genetics data (plink format), GWAS sumstats, molQTL.
Statistical Genetics: Conduct WGS/WES common and rare variant association studies, followed by post-GWAS integration using colocalization, mendelian randomization, and multi-omics (transcriptomics/proteomics) analysis.
Qualifications & Skills
Education:
MSc/PhD in Statistical Genetics, Bioinformatics, Biostatistics, Computer Science, or related quantitative field.
Experience:
Technical Skills:
Personal Attributes:
A proactive problem-solver who thrives in fast-paced, autonomous environments and is eager to master evolving technologies.
What We Offer:
Competitive Compensation:
How to Apply:
Interested candidates should submit a CV detailing their relevant experience, specific skills related to the requirements above, and suitability for the role to dreamjob+biojan26@gero.ai .
Pipeline development & maintenance
: Design, build, and maintain automated analysis pipelines for association studies, ensure code quality.
Salary packages aligned with industry standards.
Remote-First:
globally remote with flexible hours.
High-Trust Culture:
minimal-bureaucracy environment with complete ownership.
Immediate Impact:
Your contributions will drive our core therapeutic discovery engine from day one.
Publication Opportunities:
Active support for publishing.